MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Robin Guo, Lynne D. Berry, Dara L. Aisner, +8

Journal of Thoracic Oncology

OncologyMet AmplificationMedicinePathologyBronchial Neoplasm +7

Immunophenotype and Response to Immunotherapy of <i>RET</i>-Rearranged Lung Cancers

Michael Offin, Robin Guo, Stephanie L. Wu, +18

JCO Precision Oncology

Lung CancersRet RearrangementsTmb StatusMedicineImmunology +13

Characterization of on-target adverse events caused by TRK inhibitor therapy

D. Liu, James Flory, Andrew Lin, +18

Annals of Oncology

Trk Inhibitor TherapyPharmacologyTherapeutic EfficacyPharmacotherapyMedicine +4

<i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance

Robin Guo, Michael Offin, A. Rose Brannon, +22

Clinical Cancer Research

ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage

Lufen Chang, Bingsen Zhou, Shuya Hu, +4

Proceedings of the National Academy of Sciences

Reductive StressGenome InstabilityTranscriptional RegulationDna DamageBiochemistry +13

Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal Metastases

Robin Guo, Mark Schreyer, Jason C. Chang, +8

JCO Precision Oncology

Leptomeningeal MetastasesImmunologyPathologySelective Ret InhibitionSystemic Therapies +16

Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas

Robin Guo, Mariel A. DuBoff, Gowtham Jayakumaran, +5

Journal of Thoracic Oncology

Genome InstabilityMalignant DiseaseDna Damage RepairNovel Germline MutationsPathology +5

Potentially inappropriate medication use in elderly non‐Hodgkin lymphoma patients is associated with reduced survival and increased toxicities

Richard J. Lin, Helen Ma, Robin Guo, +2

British Journal of Haematology

MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies

J. Zhang, Changyou Zhou, Yan D. Zhao, +15

Journal of Thoracic Oncology

Pd-1 MabMedicinePharmacologyPathologyImmune Checkpoint Inhibitor +5

MET inhibitor resistance in patients with MET exon 14-altered lung cancers.

Robin Guo, Michael Offin, A. Rose Brannon, +16

Journal of Clinical Oncology

EngineeringPathologyMet Inhibitor ResistanceTumor BiologyIntrinsic Resistance +17